Farther Finance Advisors LLC Has $713,000 Stake in Becton, Dickinson and Company (NYSE:BDX)

Farther Finance Advisors LLC lifted its holdings in Becton, Dickinson and Company (NYSE:BDX) by 42.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,144 shares of the medical instruments supplier’s stock after acquiring an additional 944 shares during the quarter. Farther Finance Advisors LLC’s holdings in Becton, Dickinson and Company were worth $713,000 at the end of the most recent reporting period.

A number of other large investors have also bought and sold shares of the business. Wesbanco Bank Inc. raised its position in Becton, Dickinson and Company by 1.9% in the 4th quarter. Wesbanco Bank Inc. now owns 2,558 shares of the medical instruments supplier’s stock valued at $580,000 after purchasing an additional 48 shares during the last quarter. S.A. Mason LLC raised its holdings in shares of Becton, Dickinson and Company by 3.7% in the fourth quarter. S.A. Mason LLC now owns 1,414 shares of the medical instruments supplier’s stock valued at $321,000 after buying an additional 50 shares during the last quarter. Americana Partners LLC lifted its position in Becton, Dickinson and Company by 3.5% during the 4th quarter. Americana Partners LLC now owns 1,520 shares of the medical instruments supplier’s stock worth $345,000 after buying an additional 52 shares in the last quarter. Novare Capital Management LLC grew its holdings in Becton, Dickinson and Company by 5.2% during the 4th quarter. Novare Capital Management LLC now owns 1,110 shares of the medical instruments supplier’s stock worth $252,000 after acquiring an additional 55 shares during the last quarter. Finally, Pinnacle West Asset Management Inc. increased its position in Becton, Dickinson and Company by 2.7% in the 4th quarter. Pinnacle West Asset Management Inc. now owns 2,280 shares of the medical instruments supplier’s stock valued at $517,000 after acquiring an additional 60 shares in the last quarter. 86.97% of the stock is currently owned by institutional investors.

Becton, Dickinson and Company Price Performance

Shares of BDX opened at $226.43 on Friday. The stock has a market cap of $65.02 billion, a P/E ratio of 37.61, a price-to-earnings-growth ratio of 1.63 and a beta of 0.35. Becton, Dickinson and Company has a 1 year low of $218.75 and a 1 year high of $251.99. The stock’s 50-day moving average price is $232.78 and its two-hundred day moving average price is $232.33. The company has a current ratio of 1.13, a quick ratio of 0.63 and a debt-to-equity ratio of 0.69.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings data on Wednesday, February 5th. The medical instruments supplier reported $3.43 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.00 by $0.43. Becton, Dickinson and Company had a net margin of 8.47% and a return on equity of 15.74%. On average, equities analysts predict that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company announced that its board has approved a stock buyback plan on Tuesday, January 28th that permits the company to repurchase 10,000,000 outstanding shares. This repurchase authorization permits the medical instruments supplier to buy shares of its stock through open market purchases. Stock repurchase plans are often a sign that the company’s board believes its stock is undervalued.

Becton, Dickinson and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, March 31st. Investors of record on Monday, March 10th will be paid a dividend of $1.04 per share. This represents a $4.16 annualized dividend and a yield of 1.84%. The ex-dividend date of this dividend is Monday, March 10th. Becton, Dickinson and Company’s payout ratio is presently 69.10%.

Insider Buying and Selling at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, EVP Richard Byrd sold 1,940 shares of the stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $224.91, for a total transaction of $436,325.40. Following the completion of the transaction, the executive vice president now owns 7,411 shares in the company, valued at approximately $1,666,808.01. This represents a 20.75 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP David Shan sold 500 shares of the business’s stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $240.00, for a total value of $120,000.00. Following the completion of the sale, the executive vice president now owns 5,741 shares in the company, valued at approximately $1,377,840. This trade represents a 8.01 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 7,363 shares of company stock valued at $1,676,105. Company insiders own 0.36% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the stock. Piper Sandler boosted their target price on shares of Becton, Dickinson and Company from $275.00 to $280.00 and gave the stock an “overweight” rating in a research note on Tuesday, January 28th. StockNews.com upgraded shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research report on Wednesday, March 5th. Finally, Barclays increased their price objective on Becton, Dickinson and Company from $278.00 to $279.00 and gave the company an “overweight” rating in a research report on Friday, February 14th. Eight investment analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $278.29.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.